EP Patent

EP3528799A1 — Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione

Assigned to Pellficure Pharmaceuticals Inc · Expires 2019-08-28 · 7y expired

What this patent protects

Disclosed herein are pharmaceutical compositions of 5-hydroxy-2- methylnaphthalene-l,4-dione. Also disclosed are methods of treating diseases and/or conditions associated with a cancer, such as prostate cancer with such pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene…

USPTO Abstract

Disclosed herein are pharmaceutical compositions of 5-hydroxy-2- methylnaphthalene-l,4-dione. Also disclosed are methods of treating diseases and/or conditions associated with a cancer, such as prostate cancer with such pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-l,4-dione. The disclosed pharmaceutical compositions may provide improved dosage for oral administration to patients in the clinic. The disclosed pharmaceutical compositions may provide improved stability and/or shelf life.

Drugs covered by this patent

Patent Metadata

Patent number
EP3528799A1
Jurisdiction
EP
Classification
—
Expires
2019-08-28
Drug substance claim
No
Drug product claim
No
Assignee
Pellficure Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.